Abstract
For over 50 years, the only available oral anticoagulants for the treatment and prevention of thromboembolic diseases have been vitamin K antagonists (VKA) such as warfarin. Although highly effective, VKAs have many disadvantages: they have a narrow therapeutic range with a subsequent need for frequent monitoring, a >10-fold interindividual variation in dose-response, and numerous interactions with drugs and food. Thus, antithrombotics have been developed, and they emerged to circumvent these problems and limitations.
Original language | English (US) |
---|---|
Title of host publication | Vascular Surgery |
Publisher | Springer London |
Pages | 331-338 |
Number of pages | 8 |
ISBN (Electronic) | 9781447129127 |
ISBN (Print) | 9781447129110 |
DOIs | |
State | Published - Jan 1 2012 |
Externally published | Yes |
Bibliographical note
Publisher Copyright:© Springer-Verlag London 2012. All rights reserved.
Keywords
- Apixaban
- Dabigatran
- Oral anticoagulants
- Rivaroxaban
- Venous thromboembolic disease